Viatris Inc. and Ocuphire Pharma Inc. said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of...
Viatris Inc.
and Ocuphire Pharma Inc. said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision. Ryzumvi is expected to be commercially available in the U.S.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Berkshire Hathaway Inc. Cl B stock outperforms market on strong trading dayShares of Berkshire Hathaway Inc. Cl B inched 0.43% higher to $361.71 Monday, on what proved to be an all-around favorable trading session for the stock...
Leer más »
Alphabet Inc. Cl A stock rises Monday, outperforms marketShares of Alphabet Inc. Cl A inched 0.66% higher to $131.11 Monday, on what proved to be an all-around favorable trading session for the stock market, with...
Leer más »
Apple Inc. stock rises Monday, outperforms marketShares of Apple Inc. inched 0.74% higher to $176.08 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...
Leer más »
Tesla Inc. stock rises Monday, outperforms marketShares of Tesla Inc. inched 0.86% higher to $246.99 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...
Leer más »
Quantum Computing Inc. selects ASU Research Park as site for photonic chip foundryQuantum Computing Inc. has selected ASU Research Park as the future home of its new quantum photonic chip foundry.
Leer más »